Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ileabett M. Echevarria-Vargas"'
Autor:
Patricia Reyes-Uribe, Paul M. Lieberman, Jessie Villanueva, Zhong Deng, Maureen E. Murphy, Ileabett M. Echevarria-Vargas, Jerry W. Shay, Maria Paz Adrianzen-Ruesta, Qin Liu, Ilgen Mender, Dario C. Altieri, Steven Saheb
Publikováno v:
Oncogene
Targeting RAS is one of the greatest challenges in cancer therapy. Oncogenic mutations in NRAS are present in over 25% of melanomas and patients whose tumors harbor NRAS mutations have limited therapeutic options and poor prognosis. Thus far, there a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::429465a6544137f537e9b1819a60930d
http://europepmc.org/articles/PMC6062502
http://europepmc.org/articles/PMC6062502
Autor:
Adriana Roman, Perla M. Báez-Vega, Pablo E. Vivas-Mejia, Josean Flores, Ileabett M. Echevarria Vargas, María J. Marcos-Martínez, Fatma Valiyeva, Joel Encarnacion-Rosado
Publikováno v:
Oncotarget
// Perla M. Baez-Vega 1 , Ileabett M. Echevarria Vargas 1, 2 , Fatma Valiyeva 1 , Joel Encarnacion-Rosado 3 , Adriana Roman 3 , Josean Flores 4 , Maria J. Marcos-Martinez 5, 6 , Pablo E. Vivas-Mejia 1, 2 1 Comprehensive Cancer Center, University of P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb450ac532547edba1f7e221ba415388
http://europepmc.org/articles/PMC5095003
http://europepmc.org/articles/PMC5095003
Autor:
Yiling Lu, Genevieve M. Boland, Jessie Villanueva, Clemens Krepler, Adam N. Guterres, Rajasekharan Somasundaram, Christin E. Burd, Qin Liu, Dennie T. Frederick, Chaoran Cheng, Andrew V. Kossenkov, Gao Zhang, Ashani T. Weeraratna, Patricia Reyes-Uribe, Gordon B. Mills, Xiaowei Xu, Ravi K. Amaravadi, Ryan J. Sullivan, Andrew E. Aplin, Xiangfan Yin, Keith T. Flaherty, Miao Benchun, Lynn M. Schuchter, Giorgos C. Karakousis, Zhi Wei, Ileabett M. Echevarria-Vargas, Wei Xu, Meenhard Herlyn, Jennifer J.D. Morrissette
Publikováno v:
EMBO Molecular Medicine, Vol 10, Iss 5, Pp n/a-n/a (2018)
Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e391569bed8168625abc42ef6cb1b42
https://doi.org/10.15252/emmm.201708446
https://doi.org/10.15252/emmm.201708446
Autor:
Cinzia Franchin, Enrico Capobianco, Paolo Sportoletti, Silvia Rocchiccioli, Elena Guzzolino, Nicholas F. Tsinoremas, Monica Evangelista, Laura Poliseno, Alberto Mercatanti, Marianna Vitiello, Giovanni Signore, Giorgio Arrigoni, Simone Lubrano, Andrea Tuccoli, Jessie Villanueva, Ileabett M. Echevarria-Vargas, Laura Comelli, Giorgio Cozza, Letizia Pitto, Zhijie Jiang, Ettore Luzi, Andrea Marranci, Samanta Sarti
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 16, Iss 1, Pp 1-25 (2017)
Molecular Cancer, Vol 16, Iss 1, Pp 1-25 (2017)
Background The BRAF protein kinase is widely studied as a cancer driver and therapeutic target. However, the regulation of its expression is not completely understood. Results Taking advantage of the RNA-seq data of more than 4800 patients belonging
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93443682e0f01a2be6172fd143a70830
http://europepmc.org/articles/PMC5410044
http://europepmc.org/articles/PMC5410044
Autor:
Patricia Reyes-Uribe, Adam N. Guterres, Qin Liu, Xiaowei Xu, Delaine M. Zayas-Bazan Burgos, Ileabett M. Echevarria-Vargas, Amruta Ronghe, Jessie Villanueva, David W. Speicher
Publikováno v:
Cancer Research. 79:3842-3842
Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::625c7811923f96d955b8cf63f1d9e7b7
https://doi.org/10.1158/1538-7445.am2019-3842
https://doi.org/10.1158/1538-7445.am2019-3842
Publikováno v:
Cancer Research. 72:1105-1105
MicroRNAs (miRNAs) are 21-25 nucleotides regulatory involved in silencing mRNAs in a sequence specific manner. Accumulated data has established the central role of various microRNAs in tumor initiation and progression. Furthermore, recent studies rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b39dd2544705a0d5578c8afec3091a6
https://doi.org/10.1158/1538-7445.am2012-1105
https://doi.org/10.1158/1538-7445.am2012-1105